Oct 26 (Reuters) - ProMetic Life Sciences Inc
* ProMetic's plasminogen meets primary and secondary end points in pivotal phase 2/3 trial
* Says to commence filing plasminogen bla modules with fda as planned in coming weeks
* ProMetic life sciences - well tolerated, without any drug related serious adverse events in trial
* ProMetic life sciences-additional clinical data will be submitted as supplement to bla after plasminogen receives expected accelerated approval in 2017
* ProMetic life sciences-"in accordance with fast track designation granted by FDA, we will commence filing modules for plasminogen bla in coming weeks"
* ProMetic life sciences inc - "on target for an expected commercial launch of plasminogen in usa mid-next year" Source text for Eikon: Further company coverage: